Mangoceuticals (NASDAQ:MGRX) ("MangoRx"), a company specializing in men's health and wellness via telemedicine, announced today the launch of its oral Semaglutide weight loss treatment, marketed under the name "Slim."
This launch signifies a significant step for MangoRx's expansion into the weight management market.
Semaglutide, a GLP-1 receptor agonist, has gained recognition for its effectiveness in weight loss by regulating appetite according to the New England Journal of Medicine.
MangoRx's "Slim" is formulated as a convenient oral dissolvable tablet (ODT) with added Vitamin B6.
The company anticipates capitalizing on the rising demand for GLP-1 peptides like Semaglutide to grow revenue in the coming quarters.
With increasing awareness of GLP-1 treatments' efficacy in weight management, MangoRx believes it is well-positioned to capture this market growth and expand its telemedicine platform for direct-to-consumer sales.